IRIS
Cento, Valeria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.248
AS - Asia 1.698
EU - Europa 758
SA - Sud America 529
AF - Africa 107
OC - Oceania 1
Totale 6.341
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.197
SG - Singapore 1.003
BR - Brasile 449
CN - Cina 414
FI - Finlandia 182
IE - Irlanda 142
IT - Italia 106
VN - Vietnam 86
DE - Germania 72
NG - Nigeria 59
SE - Svezia 51
HK - Hong Kong 41
FR - Francia 40
GB - Regno Unito 40
NL - Olanda 38
IN - India 34
AR - Argentina 30
EC - Ecuador 21
BD - Bangladesh 20
MX - Messico 18
ZA - Sudafrica 18
BE - Belgio 15
CA - Canada 15
RU - Federazione Russa 15
JP - Giappone 14
ET - Etiopia 13
ID - Indonesia 13
TR - Turchia 13
ES - Italia 10
CO - Colombia 8
PA - Panama 8
PL - Polonia 8
PY - Paraguay 8
IQ - Iraq 7
SA - Arabia Saudita 7
UA - Ucraina 7
MA - Marocco 6
DO - Repubblica Dominicana 5
JO - Giordania 5
AM - Armenia 4
AZ - Azerbaigian 4
BG - Bulgaria 4
CL - Cile 4
CM - Camerun 4
CZ - Repubblica Ceca 4
KE - Kenya 4
MY - Malesia 4
AT - Austria 3
BO - Bolivia 3
EE - Estonia 3
GR - Grecia 3
IL - Israele 3
JM - Giamaica 3
KG - Kirghizistan 3
KZ - Kazakistan 3
MD - Moldavia 3
NP - Nepal 3
UZ - Uzbekistan 3
VE - Venezuela 3
DK - Danimarca 2
EG - Egitto 2
GE - Georgia 2
IR - Iran 2
LV - Lettonia 2
PE - Perù 2
PK - Pakistan 2
PS - Palestinian Territory 2
PT - Portogallo 2
RO - Romania 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
DZ - Algeria 1
HN - Honduras 1
HR - Croazia 1
KW - Kuwait 1
LB - Libano 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
TH - Thailandia 1
TM - Turkmenistan 1
UY - Uruguay 1
Totale 6.341
Salva come PNG Salva come JPEG
Città #
Dallas 864
Chandler 399
Singapore 320
Ashburn 281
The Dalles 268
Shanghai 218
Helsinki 181
Dublin 142
Boardman 140
New York 113
Beijing 84
Lawrence 72
Princeton 72
Benin City 59
Los Angeles 56
Council Bluffs 44
Hong Kong 40
Paris 35
São Paulo 31
Amsterdam 29
Santa Clara 28
Ho Chi Minh City 26
Bari 23
Hanoi 23
Seattle 20
London 19
Milan 17
Pune 15
Phoenix 14
Rio de Janeiro 14
Brussels 13
Wilmington 13
Munich 12
Tokyo 12
Brooklyn 11
Guayaquil 11
San Francisco 11
Boston 10
Chicago 10
Johannesburg 10
Ribeirão Preto 10
Rome 10
Addis Ababa 9
Brasília 9
Atlanta 8
Campinas 8
Naples 8
Ann Arbor 7
Belo Horizonte 7
Cagliari 7
Guarulhos 7
Haiphong 7
Warsaw 7
Alessandria 6
Ankara 6
Chennai 6
Curitiba 6
Mexico City 6
Moscow 6
Quito 6
Salvador 6
Sorocaba 6
Stockholm 6
Baghdad 5
Charlotte 5
Dhaka 5
Fortaleza 5
Guarujá 5
Jundiaí 5
Montreal 5
Amman 4
Aracaju 4
Assago 4
Baku 4
Denver 4
Nova Iguaçu 4
Petrópolis 4
Ponta Grossa 4
Roslindale 4
Bishkek 3
Cachoeirinha 3
Casablanca 3
Chapecó 3
Chisinau 3
Ciudad del Este 3
Da Nang 3
Durban 3
Itajaí 3
Las Vegas 3
Leawood 3
Mauá 3
Nairobi 3
Nanjing 3
Nova Friburgo 3
Nuremberg 3
Orem 3
Osasco 3
Poplar 3
Porto Seguro 3
Quảng Ngãi 3
Totale 4.058
Salva come PNG Salva come JPEG
Nome #
What is the impact of anti-enterococcal empirical therapy on survival of patients with enterococcal bloodstream infections? 415
Endonasal filters for the prevention and control of respiratory allergy and infections. A multi-stakeholder assessment 335
Real life experiences in HCV management in 2018 88
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C 78
Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe-short- And long-term Immune reSponSe evAluatioN in health Care workErs 74
Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 72
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future 71
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study 71
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 69
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs 68
A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy 65
Back to the future (of common respiratory viruses) 63
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 63
The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures 60
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin 59
Biotech innovations in the prevention of respiratory infectious diseases 58
Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy 57
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals 57
Detecting Hepatitis B Viral Amino Acid Sequence Mutations in Occult Hepatitis B Infections via Bayesian Partition Model 55
CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases 54
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 54
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district 53
Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon 53
Genetic diversity of human papillomavirus type 16 E6, E7, and L1 genes in Italian women with different grades of cervical lesions 52
Sex differences in electrolyte imbalances caused by SARS-CoV-2: A cross-sectional study 51
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 51
CLINICAL RELEVANCE OF NEXT GENERATION SEQUENCING ON BASELINE DETECTION OF MINORITY RESISTANCE ASSOCIATED VARIANTS IN HCV-1 PATIENTS TREATED WITH PROTEASE INHIBITORS 49
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics 49
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 48
BIPHASIC KINETICS OF HCV-RNA DECAY IS ACCOMPANIED BY AN EVEN FASTER AMINOTRANSFERASES NORMALIZATION IN ALL-DAA TREATED CIRRHOTIC PATIENTS: A DIFFERENT SCENARIO FROM INTERFERON-BASED THERAPIES 48
Beyond the distance between juridic and scientific decision-making process: An evidence-based prediction algorithm for professional liability assessment in healthcare-associated infections 48
Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality 48
Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients 47
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing 47
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018 47
Human papillomaviruses 53 and 66: clinical aspects and genetic analysis 47
Resistance to direct-acting antiviral agents: clinical utility and significance 47
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 47
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning 47
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 47
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors 46
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 46
Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype 46
BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS 46
Clinical usefulness of HCV sequencing on clinical samples with different HCV-RNA levels 46
Frontline Screening for SARS-CoV-2 Infection at Emergency Department Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR? 46
In vivo acquisition and risk of inter-species spread of bla KPC-3-plasmid from Klebsiella pneumoniae to Serratia marcescens in the lower respiratory tract 45
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 45
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 45
CHARACTERISTICS OF LAMIVUDINE RESISTANCE PROFILES IN HBV REVERSE TRANSCRIPTASE FROM A NATIONAL COLLABORATIVE STUDY OF HIV plus HBV INFECTED INDIVIDUALS ON LONG-EXPOSURE TO LAMIVUDINE INCLUDING REGIMENS 45
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 44
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 44
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy 44
CLINICAL RELEVANCE OF ACCURATE HCV GENOTYPE AND SUBTYPE ASSIGNMENT BY NS3/NS5A/NS5B DIRECT SEQUENCING IN THE ERA OF NEW DIRECT ACTING ANTIVIRAL AGENTS 44
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 44
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 44
Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era 44
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients 43
Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience 42
Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution 42
Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents 42
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 41
Effective Rapid Diagnosis of Bacterial and Fungal Bloodstream Infections by T2 Magnetic Resonance Technology in the Pediatric Population 41
Polymorphism of the HLA system and weak antibody response to BNT162b2 mRNA vaccine 41
Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety 41
The use of human immunodeficiency virus resistance tests in clinical practice 40
Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life 40
Rapid Detection and Quantification of Mycobacterium tuberculosis DNA in Paraffinized Samples by Droplet Digital PCR: A Preliminary Study 40
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 40
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 40
Prolongation of incubation time improves clinical diagnosis of Mycobacterium xenopi infection and allows susceptibility testing of mycobacterial strains against multiple antibiotics 39
Biphasic kinetics of HCV-RNA decay and quasispecies evolution during DAA-treatment are associated with risk of virological failure 39
CLINICAL RELEVANCE OF BASELINE/EARLY DETECTION AND PERSISTENCE OF RESISTANT ASSOCIATED VARIANTS IN HCV-1 PATIENTS TREATED WITH PROTEASE-INHIBITORS ASSESSED BY ULTRA-DEEP SEQUENCING 38
Epidemiology and Resistance Profiles of Bacteria Isolated From Blood Samples in Septic Patients at Emergency Department Admission: A 6-Year Single Centre Retrospective Analysis From Northern Italy 38
Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients 38
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 38
Pomegranate Extract Affects Gut Biofilm Forming Bacteria and Promotes Intestinal Mucosal Healing Regulating the Crosstalk between Epithelial Cells and Intestinal Fibroblasts 38
An overview of SARS-CoV-2 variants circulating in the 2020-2022 period in Lombardy 37
Characteristic and prevalence of NS3, NS5A and NS5B resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy 37
Early detection of NS3-resistance in HCV patients with advanced disease treated with BOC/TVR-based therapy: analysis by population- and ultra-deep sequencing 37
Intratype variations of HPV 31 and 58 in Italian women with abnormal cervical cytology 37
HCV DIVERSITY AND FIBROSIS PROGRESSION: NS5A AND CORE VARIANTS CORRELATE WITH SEVERITY OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION 36
HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals 36
Viral Respiratory Infections: New Tools for a Rapid Diagnosis 36
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 36
DIFFERENT PREVALENCE OF HCV RESISTANCE AND HCV QUANTIFICATION WITHIN BLOOD AND LIVER SAMPLES (TUMORAL AND NON TUMORAL TISSUES) OF HCC/TRANSPLANTED PATIENTS 35
High Incidence of sepsis caused by MDR bacteria in patients undergoing Percutaneous biliary drainage for the treatment of biliary obstruction 35
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 35
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 35
Increase in invasive group A streptococcal infections in Milan, Italy: a genomic and clinical characterization 35
Molecular analysis of hepatitis C virus infection in Bulgarian injecting drug users 34
KEY GENETIC SIGNATURES IN THE WHOLE pre-S1/Pre-S2/S GENE CORRELATE WITH HBV-INDUCED CARCINOGENESIS BY AFFECTING HBsAg SECRETION AND RELEASE 34
HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma 34
Key genetic markers in the full-length HBsAg gene correlate with HBV-driven carcinogenesis by affecting HBsAg secretion and release 33
EARLY-PHASE HCV KINETICS AND ROLE OF PRE-EXISTING RESISTANCE IN CIRRHOTIC OR INTERFERON-INSENSITIVE PATIENTS ON DACLATASVIR PLUS ASUNAPREVIR 33
Viral resistance in HCV infection 33
The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C 32
Virological failures to direct acting antivirals (DAA) regimens in a real life setting show frequent resistance associated variants and may require re-treatment with unconventional strategies 32
Distinct chromosomal mutation associated with cefiderocol resistance in Acinetobacter baumannii: a combined bioinformatics and mass spectrometry approach to unveil and validate the in vivo-acquired chemoresistance 31
KEY PATTERNS OF HBsAg MUTATIONS CORRELATE WITH MECHANISMS UNDERLYING LEVELS OF SERUM HBV DNA 31
Totale 5.271
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.615
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.615
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202123 0 0 0 0 0 7 6 2 5 2 1 0
2021/2022104 0 1 0 3 1 0 1 2 6 4 77 9
2022/20231.183 149 15 97 120 79 103 0 129 220 101 161 9
2023/20241.148 77 121 258 82 45 175 70 64 16 36 98 106
2024/20251.508 27 4 6 38 28 181 64 75 289 379 183 234
2025/20262.468 585 504 761 388 174 56 0 0 0 0 0 0
Totale 6.434